Investigate Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation and the Food Effect of Alpelisib Granule Formulation in Adult Healthy Volunteers

A Single-center, Randomized, Open-label, Three-period Crossover Study to Investigate the Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation, and the Food Effect of Alpelisib Granule Formulation in Adult Healthy Volunteers

The purpose of this study is to assess bioequivalence of the granule formulation of alpelisib as compared to the film-coated tablet formulation in healthy volunteers in the fed state. In addition, the food effect of the granule formulation will be investigated between the fed state and the fasted state.

Study Overview

• Status: Completed
• Conditions: Healthy Volunteers
• Intervention / Treatment: Drug: Treatment A; Drug: Treatment B; Drug: Treatment C

Detailed Description

This is a single-center, randomized, open-label, three-period six-sequence crossover study.

The study consists of a screening period followed by Periods 1, 2, and 3 and a safety follow-up. Randomization occurs at the beginning of Period 1, whereby every participant who passes the screening will be randomized to one of 6 sequences with 1:1:1:1:1:1 randomization ratio. Each sequence consists of a permutation of three treatments: A, B and C. The order of the sequence of the treatments (A, B, C) will be determined by randomization to the assigned sequence.

A total of 60 participants will be enrolled with approximately 10 participants per sequence, in order to obtain at least 48 evaluable participants for comparison of the granule formulation in fed status and the film-coated tablet formulation in fed status.

• Study Type: Interventional
• Enrollment (Actual): 33
• Phase: Phase 1

Contacts and Locations

Study Locations

• United Kingdom
  • Northern Ireland
    • Belfast, Northern Ireland, United Kingdom, BT9 6AD
      • Novartis Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female participants 18 and 55 years of age
• Female participants must be postmenopausal or not of child bearing potential.
• Participants must weigh 50 kg - 120 kg and have BMI= 18.0-30.0 kg/m2
• Participants should be in good health as determined by no clinically significant findings from the medical history, physical examination, vital signs, and ECG.
• Participant must have laboratory values (including fasting plasma glucose and HgbA1C) within the reference range at the local laboratory
• At screening, and at baseline visit of each Period, participant has vital signs which are within the protocol defined ranges

Exclusion Criteria:

• Women of childbearing potential
• Sexually active male participant with partner(s) of women of childbearing potential, UNLESS agree to comply with highly effective contraception AND use a condom
• Participant with
• significant illness, including infections, or hospitalization within the 30 days prior to dosing.
• diabetes mellitus or participants with fasting plasma glucose (FPG) levels > 100 mg/dL or >5.55 mmol/L.
• clinically significant risk of developing diabetes mellitus during the study
• Use of:
• tobacco products within 3 months prior to first dosing
• drug or alcohol abuse within 12 months prior to first dose
• alcohol within 48 hours prior to the dosing of each treatment period.
• any prescription or non-prescription, herbal medication, dietary supplements or vitamins during 14 days prior to dosing..
• History of :
• clinically significant hematologic, renal, endocrinologic, pulmonary, cardiovascular, hepatic, or allergic disease, medically documented. including uncontrolled hypertension, interstitial lung disease, or other causes of dyspnea, acute pancreatitis within 1 year of screening or past medical
• chronic pancreatitis.
• cardiac disease
• immunodeficiency diseases
• malignancy of any organ system carcinoma of the skin or in situ cervical cancer), within 5 years,
• erythema multiform (EM), Steven-Johnson-Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN).
• history or presence of
• any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs.
• clinically significant ECG abnormalities or a family prolonged QT-interval syndrome.
• chronic infection with Hepatitis B (HBV) or Hepatitis C (HCV).

Other inclusion/exclusion criteria may apply

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Sequence 1; Participants will receive a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 2 and a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 3.	Drug: Treatment A; Single oral dose of alpelisib film-coated tablet at 50 mg in fed state; Drug: Treatment B; Single oral dose of alpelisib granule at 50 mg in fed state; Drug: Treatment C; Single oral dose of alpelisib granule at 50 mg in fasted state
Experimental: Sequence 2; Participants will receive a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 2 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 3.	Drug: Treatment A; Single oral dose of alpelisib film-coated tablet at 50 mg in fed state; Drug: Treatment B; Single oral dose of alpelisib granule at 50 mg in fed state; Drug: Treatment C; Single oral dose of alpelisib granule at 50 mg in fasted state
Experimental: Sequence 3; Participants will receive a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 1 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 2 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 3.	Drug: Treatment A; Single oral dose of alpelisib film-coated tablet at 50 mg in fed state; Drug: Treatment B; Single oral dose of alpelisib granule at 50 mg in fed state; Drug: Treatment C; Single oral dose of alpelisib granule at 50 mg in fasted state
Experimental: Sequence 4; Participants will receive a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 2 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A).	Drug: Treatment A; Single oral dose of alpelisib film-coated tablet at 50 mg in fed state; Drug: Treatment B; Single oral dose of alpelisib granule at 50 mg in fed state; Drug: Treatment C; Single oral dose of alpelisib granule at 50 mg in fasted state
Experimental: Sequence 5; Participants will receive a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 1 followed by a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C) in period 2 followed by a single oral dose of alpelisib granule at 50 mg in fed state (treatment B).	Drug: Treatment A; Single oral dose of alpelisib film-coated tablet at 50 mg in fed state; Drug: Treatment B; Single oral dose of alpelisib granule at 50 mg in fed state; Drug: Treatment C; Single oral dose of alpelisib granule at 50 mg in fasted state
Experimental: Sequence 6; Participants will receive a single oral dose of alpelisib granule at 50 mg in fed state (treatment B) in period 1 followed by a single oral dose of alpelisib film-coated tablet at 50 mg in fed state (treatment A) in period 2 followed by a single oral dose of alpelisib granule at 50 mg in fasted state (treatment C).	Drug: Treatment A; Single oral dose of alpelisib film-coated tablet at 50 mg in fed state; Drug: Treatment B; Single oral dose of alpelisib granule at 50 mg in fed state; Drug: Treatment C; Single oral dose of alpelisib granule at 50 mg in fasted state

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum concentration (Cmax) of alpelisib for Treatment A and Treatment B	Blood samples will be collected at specified time points to compare Cmax of the test formulation (Treatment B: granule formulation in fed state) versus the reference formulation (Treatment A: the film-coated tablet formulation in fed state). PK parameters will be calculated using noncompartmental data analysis of plasma concentration-time data	Period 1, 2 and 3 at pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12. 24, 48, 72 and 96 hours post-dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum concentration (Cmax) of alpelisib for Treatment B and Treatment C	Blood samples will be collected at specified time points to compare Cmax of the granule formulation in the fed state (Treatment B) versus the granule formulation in the fasted state (Treatment C). PK parameters will be calculated using noncompartmental data analysis of plasma concentration-time data.	Period 1, 2 and 3 at pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12. 24, 48, 72 and 96 hours post-dose
Area under plasma concentration time curve (AUC) from zero to 96 hours post dose of alpelisib for Treatment A, Treatment B and Treatment C	Blood samples will be collected at specified time points to calculate AUC0-96 of alpelisib after a single oral dose of alpelisib film coated tablet formulation in fed state (Treatment A), after a single oral dose of alpelisib granule formulation in fed state (Treatment B), after a single oral dose of alpelisib granule formulation in fasted state (Treatment C). PK parameters will be calculated using noncompartmental data analysis of plasma concentration-time data	Period 1, 2 and 3 at pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12. 24, 48, 72 and 96 hours post-dose

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (Actual): February 3, 2022
• Primary Completion (Actual): November 9, 2022
• Study Completion (Actual): November 9, 2022

Study Registration Dates

• First Submitted: January 4, 2022
• First Submitted That Met QC Criteria: January 4, 2022
• First Posted (Actual): January 19, 2022

Study Record Updates

• Last Update Posted (Estimate): December 28, 2022
• Last Update Submitted That Met QC Criteria: December 27, 2022
• Last Verified: December 1, 2022

More Information

Terms related to this study

• Keywords: adult; bioequivalence; BYL719; food effect; alpelisib; three-period six sequence crossover
• Other Study ID Numbers: CBYL719F12101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No